AngioDesign

Executive Summary

AngioDesign is a UK-based biopharmaceutical company pioneering the rational design of next-generation, domain-selective inhibitors of Angiotensin-Converting Enzyme (ACE) for cardiovascular and other non-communicable diseases. Leveraging 3D structural biology, the company aims to create enhanced therapeutics that selectively target the N-domain of ACE, potentially reducing side effects associated with conventional ACE inhibitors while maintaining efficacy. Founded in 2015, AngioDesign operates in the small molecules category and is privately held. Though early-stage with limited public data, the company's approach addresses a validated target with high clinical relevance. Their platform could also enable combination therapies with other inhibitors, broadening the therapeutic scope. The company's progress and future value hinge on advancing its lead candidate through preclinical development and securing partnerships or funding to support clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Completion of preclinical toxicology studies and IND-enabling activities60% success
• Q4 2026Announcement of a strategic partnership or licensing deal for domain-selective ACE inhibitors40% success
• Q2 2026Publication of preclinical efficacy data in a peer-reviewed journal or at a major cardiovascular conference70% success